AVEO Pharmaceuticals, Inc. (AVEO) stock rallied over 2.43% intraday to trade at $7.17 a share on NASDAQ. The stock opened with a gain of 7.01% at $6.93 and touched an intraday high of $7.25, rising 2.43% against the last close of $7. The stock went to a low of $7 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue42.3 Million
5Y Sales Change75.90%
Fiscal Year Ends2021-12-30
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; AstraZeneca PLC; and Bristol Myers Squibb. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) stock price is $7.17 as of the last check on Wednesday, July 6. During the trading session, AVEO stock reached the peak price of $7.25 while $7 was the lowest point it dropped to.
The NASDAQ listed AVEO is part of Biotechnology industry that operates in the broader Health Care sector. AVEO Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients.
Ms. Danielle Holland
Sr. Corp. Counsel & Corp. Sec.
Mr. Kevin Peacock
VP of Marketing
Mr. Michael P. Bailey
CEO, Pres & Director
Mr. Erick Lucera CFA, CPA
Chief Financial Officer
AVEO stock traded closed the last session at $7.17, which is $0.17 or 2.43% lower than its previous close of $7. AVEO's current trading price is 134.31% lower than its 52-week high of $7.55 where as its distance from 52-week low of 3.06% is -5.03%.
Number of AVEO employees currently stands at -. AVEO operates from 30 Winter Street, Boston, MA 02108, United States.
Official Webiste of $AVEO is: https://www.aveooncology.com
AVEO stock volume for the day was 366,282 shares while in the previous session number of AVEO shares traded was 365,724 . The average number of AVEO shares traded daily for last 3 months was 227.48 Thousands.
The percentage change in AVEO stock occurred in the recent session was 2.43% while the dollar amount for the price change in AVEO stock was $0.17.
In the recent session, the day high for AVEO stock was $7.25 while the low for AVEO stock touched on the day was $7.
The market value of AVEO currently stands at 241.7 Million with its latest stock price at $7.17 and 34.48 Million of its shares outstanding.